1. EXPRESS: Response Rates at Week 10 0.0 25.6 0 20 40 60 80 100 Placebo (n=77) Infliximab 5 mg/kg (n=301) Per cent of patients Per cent of patients with PASI Score of 0 (Clear) 0.0 39.0 Placebo (n=77) Infliximab 5 mg/kg (n=292) Per cent of patients with Physician’s Global Assessment of Cleared 1.3 47.1 Placebo (n=77) Infliximab 5 mg/kg (n=291) Per cent of patients with DLQI of 0 Adapted from presentations during Dermatology Update 2006

2. EXPRESS: Phase III *P<0.001 vs. placebo 0 20 40 60 80 100 Placebo (n=77)Infliximab 5 mg/kg (n=301) Per cent of patients with  75% Improvement in PASI 02610142224 Weeks * * * * * 80.4%82.2% Adapted from presentations during Dermatology Update 2006

3. Efficacy of Systemic Therapies in Psoriasis 21% 27% 34% 49% 80% 0% 20% 40% 60% 80% 100% Alefacept i.m. 15 mgEfalizumab 1 mg/kg/wk Etanercept 25 mg BIWEtanercept 50 mg BIW Infliximab 5 mg/kg 83% 71% 68% 60% 50% 0% 20% 40% 60% 80% 100% PUVACyAUVBMTXFAE Alefacept: Lebwohl et al. Arch Dermatol 2003 Efalizumab: Gordon et al. JAMA 2003 Menter et al. Arch Dermatol 2005 Etanercept: Leonardi et al. N Engl J Med 2003 Infliximab: Reich et al. Lancet 2005 PUVA, UVB: Spuls et al. Br J Dermatol 1997 CyA, MTX: Heydendael et al. N Engl J Med 2003 FAE: Altmeyer et al. J Am Acad Dermatol 1994 PASI 75 or equivalent; induction therapy (10 to 16 weeks) Adapted from presentations during Dermatology Update 2006

4. Treat active TB to resolution New patient office visit PPD test positive and active TB Initiate latent TB treatment Initiate therapy Administer appropriate TB screening test (PPD skin test + CXR + family history) Evaluate test results Test negative Initiate therapy PPD test positive and normal CXR Arend SM et al. Neth J Med 2003;61(4):111-9 Algorithm for TB Testing: European-based Recommendations